Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dovitinib - Allarity Therapeutics

Next Previous
Drug Profile

Dovitinib - Allarity Therapeutics

Alternative Names: CHIR-258; Dovitinib lactate; GFKI-258; Growth factor kinase inhibitor 258; TKI-258

Latest Information Update: 17 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Academic and Community Cancer Research United; Allarity Therapeutics; Case Comprehensive Cancer Center; Georgetown University; National Cancer Institute (USA); Novartis; Ontario Clinical Oncology Group; University of California, Davis; University of Texas M. D. Anderson Cancer Center; University of Virginia; Yonsei University Health System
  • Class Antineoplastics; Benzimidazoles; Lactates; Piperazines; Quinolones; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Type 3 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adenoid cystic carcinoma; Osteosarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Renal cancer
  • Phase II Endometrial cancer; Gastrointestinal stromal tumours; HER2 negative breast cancer; Liver cancer
  • Phase I Ovarian cancer; Solid tumours
  • Preclinical Osteosarcoma
  • Discontinued Acute myeloid leukaemia; Adenoid cystic carcinoma; Colorectal cancer; Gastric cancer; Glioblastoma; Haematological malignancies; Malignant melanoma; Malignant-mesothelioma; Multiple myeloma; Neuroendocrine tumours; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Thyroid cancer; Urogenital cancer; Von Hippel-Lindau disease

Most Recent Events

  • 13 Oct 2023 Dovitinib - Allarity Therapeutics receives Orphan Drug status for Osteosarcoma (In adolescents, In children) in USA
  • 02 Oct 2023 Oncoheroes Biosciences plans a clinical trial for Paediatric cancer
  • 02 Oct 2023 Oncoheroes Biosciences approves IND application for dovitinib in Paediatric cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top